On October 9, 2018, Kodiak Sciences Inc. (Kodiak), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced the closing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $10.00 per share. The shares began trading on the Nasdaq Global Market under the ticker symbol "KOD" on October 4, 2018. Wilson Sonsini Goodrich & Rosati is representing Kodiak in the offering.

Morgan Stanley and BofA Merrill Lynch acted as joint book-running managers for the offering. Barclays acted as a book-running manager for the offering. Chardan acted as lead manager.

The Wilson Sonsini team representing Kodiak includes partners Jeff Saper and Michael Nordtvedt and associates Bryan King and Cody Gaynor.

For more information, please see Kodiak's press release.